关于润本生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：润本生物技术股份有限公司 审计单位：广东司农会计师事务所（特殊普通合伙） 联系电话：020-39391992 关于润本生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 司农专字[2025]24009540021 号 润本生物技术股份有限公司全体股东： 我们接受委托，依据《中国注册会计师审计准则》审计了润本生物技术股 份有限公司（以下简称"润本股份"）2024 年 12 月 31 日的合并及母公司资产 负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表和合并及 母公司所有者权益变动表以及财务报表附注，并于 2025 年 4 月 24 日出具了司 农审字[2025]24009540015 号的无保留意见审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资 金往来、对外担保的监管要求》的要求及上海证券交易所《上海证券交易所上 市公司自律监管指南第 2 号——业务办理》的规定，润本股份管理层编制了后 附的润本生物技 ...

公司代码：603193 公司简称：润本股份 润本生物技术股份有限公司 2024年度内部控制评价报告 润本生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导 ...

重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 证券代码：603193 证券简称：润本股份 公告编号：2025-015 润本生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 15 日 15 点 00 分 召开地点：广东省广州市天河区珠江新城华夏路 28 号富力盈信大厦 40 楼润 本生物技术股份有限公司会议室 股东大会召开日期：2025年5月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 15 日 至2025 年 5 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平 ...

证券代码：603193 证券简称：润本股份 公告编号：2025-008 润本生物技术股份有限公司 第二届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 润本生物技术股份有限公司（以下简称"公司"）第二届监事会第五次会议 于2025 年 4 月 24 日在公司会议室以现场方式召开。会议通知已于2024 年 4 月 14 日通过书面文件的方式送达各位监事。本次会议应出席监事 3 人，实际出席 监事 3 人。董事会秘书吴伟斌先生列席了本次会议。本次会议的召集、召开和表 决程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 经各位监事认真审议，会议形成了如下决议。 二、监事会会议审议情况 （一）审议通过《关于<2024 年年度报告及摘要>的议案》 经审议，监事会认为，公司董事会编制和审核《2024年年度报告及其摘要》 的程序符合相关法律法规，报告内容真实、准确、完整地反映了公司2024年度的 财务状况和经营情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容 ...

证券代码：603193 证券简称：润本股份 公告编号 2025-009 润本生物技术股份有限公司 ● 本次利润分配方案已经 2025 年 4 月 24 日召开的第二届董事会第七次会议和 第二届监事会第五次会议审议通过，尚待公司 2024 年年度股东大会审议通过后方 可实施。 ● 公司不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以下简 称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警 示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经广东司农会计师事务所（特殊普通合伙）审计，公司 2024 年度归属于上市 公司股东的净利润 300,161,748.03 元。截至 2024 年 12 月 31 日，公司母公司报表 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 重要内容提示： ● 每 10 股派发现金红利 2.30 元（含税）。 ● 本次利润分配以实施权益分派股权登记日登记的总股本为基数向润本生物技 术股份有限公司（以下简称"公司" ...

申万宏源证券承销保荐有限责任公司 关于润本生物技术股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 经中国证券监督管理委员会《关于同意润本生物技术股份有限公司首次公 开发行股票注册的批复》(证监许可[2023]1631号)核准，公司于2023年9月27日 首次公开发行人民币普通股（A股）60,690,000股，发行价格为人民币17.38元/ 股，募集资金总额为人民币105,479.22万元，扣除不含税的发行费用人民币 8,356.37万元后，实际募集资金净额为人民币97,122.85万元。上述募集资金已于 2023年10月11日全部到账，并经容诚会计师事务所（特殊普通合伙）审验，于 2023年10月12日出具了验资报告（容诚验字[2023]510Z0017号）。 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"，"保 荐人"）作为润本生物技术股份有限公司（以下简称"润本股份"或"公司"）首次 向社会公开发行人民币普通股（A股）的保荐人，根据《证券发行上市保荐业 务管理办法》《上市公司监管指引第2号——上市公司募集资金管理和使用的监 管要求》《上海证券交易所上市公司自律监管指引第1 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,318,176,100.04, representing a year-on-year increase of 27.61% compared to ¥1,032,954,606.07 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥300,161,748.03, reflecting a growth of 32.80% from ¥226,027,081.04 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥289,229,513.93, up 32.28% from ¥218,647,676.45 in 2023[23]. - Cash flow from operating activities for 2024 was ¥257,240,496.51, a slight increase of 1.87% compared to ¥252,520,758.30 in 2023[23]. - Total assets at the end of 2024 amounted to ¥2,219,337,493.41, a 9.93% increase from ¥2,018,870,919.90 at the end of 2023[23]. - The net assets attributable to shareholders increased to ¥2,080,453,702.55, marking an 8.29% rise from ¥1,921,258,411.52 in 2023[23]. - Basic earnings per share increased to 0.74 RMB, up 15.63% from 0.64 RMB in 2023[24]. - The diluted earnings per share also rose to 0.74 RMB, reflecting the same percentage increase of 15.63%[24]. - The weighted average return on equity decreased to 14.91%, down 7.73 percentage points from 22.64% in 2023[24]. Product Development and Innovation - The company launched several new products, including children's sunscreen and various egg yolk oil products, enhancing its product matrix[32]. - Over 90 new or upgraded products were launched during the reporting period, including a children's sunscreen and a timed heater for mosquito repellent liquid[34]. - The company obtained 13 new patents in 2024, bringing the total to 95 patents, including 12 invention patents and 71 design patents[35]. - The company participated in drafting 7 group standards, including the "Children's Ointment" standard, enhancing its role in industry standards[35]. - The company continues to invest in R&D to enhance its core competitiveness, focusing on integrating research, production, and sales[34]. Market Position and Sales Strategy - The company has established a comprehensive online and offline sales network, maintaining a high market share on platforms like Tmall and JD[32]. - The company operates a multi-channel sales model, including direct online sales and non-platform distributors, to reach consumers effectively[39]. - The company emphasizes product quality and adheres to national quality standards, ensuring compliance with international guidelines such as ISO22716:2007[41]. - The company received multiple awards for its products, enhancing brand influence and recognition in the market[32]. - The company plans to continue expanding its product offerings and market presence, focusing on innovation and quality to maintain competitive advantages[67]. Financial Management and Investments - The company plans to invest CNY 700 million in the "Runben Intelligent Manufacturing Future Factory Project" approved on September 23, 2024[88]. - Cash received from investment recoveries surged by 225.52% to ¥1,892,401,259.22, primarily due to the redemption of time deposits[60]. - Cash received from investment income rose significantly by 767.41% to ¥41,034,121.29, attributed to increased interest income from large time deposits[60]. - The company has established a comprehensive internal control and compliance management system to mitigate risks and ensure sustainable development[36]. - The company is focused on building a digital supply chain management system to enhance supply chain efficiency and value creation[44]. Corporate Governance and Compliance - The company has provided a standard unqualified audit report from Guangdong Sinong Accounting Firm[5]. - The management has highlighted potential risks in the future development discussions within the report[10]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not experienced any major changes in the business operations of its controlling shareholders that would affect its independence[104]. - The company has not reported any significant changes in the business operations of its controlling shareholders that would affect its independence[104]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of ¥2.30 per 10 shares to all registered shareholders[6]. - The cash dividend amount distributed was RMB 93,056,462.22, representing 31.00% of the net profit attributable to ordinary shareholders[137]. - Over the last three fiscal years, the cumulative cash dividend amount was RMB 234,664,122.12, with a cash dividend ratio of 89.19%[139]. - The company maintains a continuous and stable profit distribution policy, prioritizing cash dividends when conditions are met[125]. - The company ensures that small and medium shareholders have ample opportunities to express their opinions and protect their rights during profit distribution discussions[135]. Risk Factors and Market Challenges - The birth rate in China has been declining since 2017, projected to drop to 6.77‰ in 2024, resulting in a 53.42% decrease in newborns compared to the peak of 17.86 million in 2016, which may impact the baby care industry[99]. - The company is facing intensified competition in the daily chemical industry, with numerous domestic and international players, and a low market concentration, which could adversely affect its operations if it fails to invest in product development and market expansion[98]. - The company is implementing fundraising projects including the Huangpu factory R&D and industrialization project, channel construction and brand promotion project, and information system upgrade project, which may face risks if market conditions change significantly[99]. Employee and Talent Management - The company has strengthened its talent acquisition strategy, bringing in experienced professionals to enhance its management team[36]. - The total number of employees in the parent company is 297, and in major subsidiaries, it is 624, resulting in a total of 921 employees[119]. - The professional composition includes 369 production personnel, 323 sales personnel, 151 technical personnel, and 78 management personnel[119]. - The training program emphasizes employee development through various training methods, including new employee training and internal departmental training[122]. Environmental and Social Responsibility - The company invested RMB 98.32 million in environmental protection during the reporting period[145]. - The company implemented carbon reduction measures, resulting in a reduction of 143,882.85 tons of CO2 equivalent emissions[149]. - The company donated a total of RMB 10.59 million to various charitable projects, benefiting approximately 4,000 individuals[151].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 240,031,623.59, representing a 44.00% increase compared to CNY 166,683,251.48 in the same period last year[4]. - Net profit attributable to shareholders was CNY 44,197,373.22, up 24.60% from CNY 35,472,246.48 year-on-year[4]. - The basic earnings per share increased to CNY 0.11, reflecting a growth of 22.22% compared to CNY 0.09 in the previous year[4]. - Operating profit for the first quarter of 2025 reached CNY 50,473,859.26, up from CNY 35,024,485.64 in the same period last year, reflecting a growth of 44.3%[20]. - The company reported a total profit of CNY 50,399,869.74 for the first quarter of 2025, compared to CNY 40,041,949.75 in the first quarter of 2024, representing an increase of 25.5%[20]. - Total revenue from sales of goods and services in the first quarter of 2025 was CNY 253,225,409.69, compared to CNY 174,900,831.91 in the first quarter of 2024, marking an increase of 44.6%[22]. Cash Flow and Expenses - The net cash flow from operating activities improved to -CNY 14,999,804.39, compared to -CNY 28,319,378.91 in the same period last year[4]. - The cash flow from operating activities for the first quarter of 2025 was a net outflow of CNY -14,999,804.39, an improvement from CNY -28,319,378.91 in the first quarter of 2024[23]. - Investment activities resulted in a net cash outflow of CNY -28,833,237.08 in the first quarter of 2025, compared to CNY -150,386,039.73 in the same period last year, indicating a significant reduction in cash outflow[23]. - The company incurred sales expenses of CNY 75,492,319.13 in the first quarter of 2025, which is an increase of 50.1% compared to CNY 50,251,470.27 in the first quarter of 2024[20]. - Research and development expenses for the first quarter of 2025 were CNY 7,690,859.31, up from CNY 6,882,342.91 in the same period last year, reflecting a growth of 11.7%[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,301,566,119.19, a 3.71% increase from CNY 2,219,337,493.41 at the end of the previous year[5]. - The total current assets as of March 31, 2025, amounted to RMB 1,663,502,833.92, an increase from RMB 1,594,831,016.45 at the end of 2024[14]. - The total liabilities as of March 31, 2025, were RMB 176,915,043.42, an increase from RMB 138,883,790.86 at the end of 2024[16]. - The total non-current assets as of March 31, 2025, were RMB 638,063,285.27, compared to RMB 624,506,476.96 at the end of 2024[15]. - The company's equity attributable to shareholders as of March 31, 2025, was RMB 2,124,651,075.77, up from RMB 2,080,453,702.55 at the end of 2024, showing an increase of 2.1%[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,364[9]. - The largest shareholder, Guangzhou Zhuofan Investment Holdings Co., Ltd., held 44.5% of the shares, totaling 180,387,000 shares[9]. Revenue Drivers - The increase in revenue was primarily driven by growth in online sales channels, particularly through Douyin, and non-platform sales channels[8]. - The total operating costs for the first quarter of 2025 were RMB 195,094,181.98, up 49.8% from RMB 130,256,736.28 in the same period last year[18]. - The operating cost specifically for the first quarter of 2025 was RMB 101,599,521.25, which represents an increase of 37.5% from RMB 73,849,098.24 in the first quarter of 2024[18]. Accounts Receivable - The company reported a significant increase in accounts receivable, which rose to RMB 21,439,712.40 as of March 31, 2025, compared to RMB 13,592,744.31 at the end of 2024, marking an increase of 57.5%[14]. Non-Recurring Gains - The company reported non-recurring gains of CNY 5,580,859.91 for the period, after accounting for tax effects[7]. Return on Equity - The weighted average return on equity rose to 2.10%, an increase of 0.27 percentage points from 1.83%[5]. Cash and Cash Equivalents - The cash and cash equivalents decreased to RMB 62,376,401.76 as of March 31, 2025, from RMB 106,589,293.81 at the end of 2024, indicating a decline of 41.5%[13]. - Total cash and cash equivalents at the end of the first quarter of 2025 were CNY 62,376,401.76, down from CNY 104,739,996.73 at the end of the first quarter of 2024[24].

润本生物技术股份有限公司 舆情管理制度 第一章 总则 第一条 为提高润本生物技术股份有限公司（以下简称"公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股 价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者和公司的合 法权益，根据相关法律、法规、规范性文件等和《润本生物技术股份有限公司章 程》（以下简称"公司章程"）的规定，结合公司实际情况，特制定本制度。 第二条 本制度所称舆情，包括： （一）报刊、电视、网络等媒体对公司进行的负面报道、不实报道； （四）其他涉及公司信息披露且可能对公司股票交易价格产生较大影响的事 件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受损失，已经或可能造成公司股票交易价格异常波动的负面 舆情； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （二）一般舆情：指除重大舆情之外的其他舆情。 第四条 本制度适用于本公司及合并报表范围内的各子公司。 第二章 舆情管理的组织体系及其工 ...

润本生物技术股份有限公司 2024 年度独立董事述职报告 ——赵晓明 各位董事： 本人作为润本生物技术股份有限公司（以下简称"公司"）的独立董事，根 据《中华人民共和国公司法》《公司章程》和公司《独立董事工作制度》等相关 法律法规和规章制度的规定和要求，在 2024 年度，本人勤勉尽责地履行独立董 事的职责和义务，认真审慎地行使公司和股东所赋予的权利，对公司董事会审议 的相关重大事项发表了公正、客观的独立意见。现将 2024 年度本人履行独立董 事职责情况报告如下： 一、独立董事的基本情况 经 2023 年第四次临时股东大会审议通过，第二届董事会独立董事为本人与 郑怡玲女士，占董事会人数超过三分之一，符合相关法律法规。2024 年度，本 人的任期为 2024 年 1 月 1 日至 2024 年 12 月 31 日。 （一）个人工作履历、专业背景及兼职情况 赵晓明，男，1964 年 11 月出生，中国国籍，无永久境外居留权，研究生学 历，中国注册会计师。历任经济管理学院教师、监察处副处长、审计处副处长、 财务处处长、基建处正处级干部。退休后现被仲恺农业工程学院返聘，兼任仲恺 教育基金会理事长、广东朝阳电子科技股 ...